Key result
Pharmacological CAV therapies offer modest progression benefits but carry significant toxicity risks.
Why the study?
Cardiac allograft vasculopathy causes up to one-third of deaths at 5 years post-cardiac transplantation, and the evidence for drugs used in its prevention and treatment requires review.
This review summarizes the evidence for currently available drugs, including statins, calcium channel blockers, and immunosuppressive agents, in the prevention and treatment of cardiac allograft vasculopathy.
Review summarizes limited pharmacologic options for CAV; leaves open need for targeted trials of novel agents.
Cardiac allograft vasculopathy (CAV) of heart transplants is responsible for up to one-third of deaths at 5 years following cardiac transplantation.Risk factors for CAV include both traditional risk factors and immune factors.Drugs used for prevention and treatment of CAV include statins, calcium channel blockers and immunosuppressive agents.This review discusses the currently available drugs for CAV, the evidence behind their use, and future targets of therapy.
No takes yet. Share an insight, caveat, or question.
Shuchita Gupta (2014) conducted a review in Cardiac allograft vasculopathy. Pharmacological therapies (statins, calcium channel blockers, immunosuppressive agents) was evaluated. Pharmacological therapies for cardiac allograft vasculopathy, including statins and immunosuppressive agents, offer modest efficacy in preventing disease progression but are limited by significant toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: